Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced epithelial ovarian cancer
Jamie L. Lesnock, Coreen Farris, Thomas C. Krivak, Kenneth J. Smith, Maurie MarkmanVolume:
122
Year:
2011
Language:
english
Pages:
6
DOI:
10.1016/j.ygyno.2011.05.014
File:
PDF, 344 KB
english, 2011